Earlier this morning, Alzinova reported their 2018 year-end bulletin. The financials and specifically, cash burn, were according to our estimates. Upcoming news flow includes a planned listing on OMX Nasdaq First North and initiation of a phase Ib study on early Alzheimer patients.